A Phase I Study of CC-90002, a Monoclonal Antibody Targeting CD47, in Patients with Relapsed and/or Refractory (R/R) Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndromes (MDS): Final Results

被引：37
|
作者：
Zeidan, Amer M. [1 ,2 ]
DeAngelo, Daniel J. [3 ]
Palmer, Jeanne M. [4 ]
Seet, Christopher S. [5 ]
Tallman, Martin S. [6 ]
Wei, Xin [7 ]
Li, Ying Fei [8 ]
Hock, Nanette [9 ]
Burgess, Michael R. [9 ]
Hege, Kristen [9 ]
Stock, Wendy [10 ]
机构：
[1] Yale Univ, New Haven, CT USA
[2] Yale Canc Ctr, New Haven, CT USA
[3] Dana Farber Canc Inst, Boston, MA 02115 USA
[4] Mayo Clin, Phoenix, AZ USA
[5] Univ Calif Los Angeles, David Geffen Sch Med, Div Hematol Oncol, Los Angeles, CA 90095 USA
[6] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[7] Celgene Corp, Berkeley, NJ USA
[8] Celgene Corp, Summit, NJ USA
[9] Celgene Corp, San Francisco, CA USA
[10] Univ Chicago Med, Chicago, IL USA
来源：
BLOOD | 2019年 / 134卷
关键词：
D O I：
10.1182/blood-2019-125363
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1320
引用
收藏
页数：6
相关论文
共 50 条
  • [1] Phase 1 study of anti-CD47 monoclonal antibody CC-90002 in patients with relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndromes
    Amer M. Zeidan
    Daniel J. DeAngelo
    Jeanne Palmer
    Christopher S. Seet
    Martin S. Tallman
    Xin Wei
    Heather Raymon
    Priya Sriraman
    Stephan Kopytek
    Jan Philipp Bewersdorf
    Michael R. Burgess
    Kristen Hege
    Wendy Stock
    Annals of Hematology, 2022, 101 : 557 - 569
  • [2] Phase 1 study of anti-CD47 monoclonal antibody CC-90002 in patients with relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndromes
    Zeidan, Amer M.
    DeAngelo, Daniel J.
    Palmer, Jeanne
    Seet, Christopher S.
    Tallman, Martin S.
    Wei, Xin
    Raymon, Heather
    Sriraman, Priya
    Kopytek, Stephan
    Bewersdorf, Jan Philipp
    Burgess, Michael R.
    Hege, Kristen
    Stock, Wendy
    ANNALS OF HEMATOLOGY, 2022, 101 (03) : 557 - 569
  • [3] A Phase I/IIa Study of Lemzoparlimab, a Monoclonal Antibody Targeting CD47, in Patients with Relapsed and/or Refractory Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS): Initial Phase I Results
    Qi, Junyuan
    Li, Jian
    Jiang, Bin
    Jiang, Bo
    Liu, Hongzhong
    Cao, Xinxin
    Zhang, Meixiang
    Meng, Yuan
    Ma, Xiaoyu
    Jia, Yingmin
    Guo, Jiyuan
    Zhang, Yanni
    Huang, Wei
    Wang, Jianxiang
    BLOOD, 2020, 136
  • [4] Final Results of Phase 2, Open-Label Study of E7070, Idarubicin and Cytarabine in Patients (Pts) with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)
    Assi, Rita
    Kantarjian, Hagop M.
    Cortes, Jorge E.
    Kadia, Tapan
    Pemmaraju, Naveen
    Jabbour, Elias J.
    Jain, Nitin
    Daver, Naval
    Uehara, Taisuke
    Owa, Takashi
    Borthakur, Gautam
    BLOOD, 2017, 130
  • [5] A phase I/II study of topotecan, mitoxantrone and etoposide in relapsed/refractory acute myeloid leukemia (AML), myeloid blast crisis and high risk myelodysplastic syndromes (MDS).
    Nand, S
    Stiff, P
    Beltran, O
    Godwin, J
    BLOOD, 1999, 94 (10) : 234B - 234B
  • [6] A Phase I Study of the Vascular Disrupting Combretastatin, OXi4503, in Patients with Relapsed and Refractory Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS)
    Cogle, Christopher R.
    Gonzalez, Andres
    Pettiford, Leslie
    Meacham, Amy
    Wise, Elizabeth
    Norkin, Maxim
    Chaplin, David
    Balkissoon, Jai
    Hsu, Jack W.
    Brown, Randy A.
    Hiemenz, John W.
    Wingard, John R.
    BLOOD, 2012, 120 (21)
  • [7] A Phase I Study Of The Vascular Disrupting Combretastatin, OXi4503, In Patients With Relapsed and Refractory Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS)
    Turner, Daniel
    Gonzalez, Andres
    Pettiford, Leslie
    Meacham, Amy
    Wise, Elizabeth
    Bosse, Raphael C.
    Chaplin, Dai
    Hsu, Jack W.
    Brown, Randy A.
    Hiemenz, John W.
    Norkin, Maxim
    Wingard, John R.
    Cogle, Christopher R.
    BLOOD, 2013, 122 (21)
  • [8] A phase I/II study of induction therapy with topotecan, mitoxantrone and etoposide in relapsed/refractory acute myeloid leukemia (AML), myeloid blast crisis and high risk myelodysplastic syndromes (MDS).
    Nand, S
    Godwin, J
    White, C
    Beltran, O
    Stiff, P
    BLOOD, 2000, 96 (11) : 214B - 214B
  • [9] Update of a phase I study of sorafenib in patients with refractory/relapsed acute myeloid leukemia or high-risk myelodysplastic syndrome
    Delmonte, John, Jr.
    Kantarjian, Hagop M.
    Andreef, Michael
    Faderl, Stefan
    Wright, John J.
    Zhang, Weiguo
    Konopleva, Marina
    Verstovsek, Srdan
    Borthakur, Gautam
    Ravandi, Farhad
    Cortes, Jorge
    BLOOD, 2007, 110 (11) : 272A - 273A
  • [10] Venetoclax-Based Preconditioning Followed by Immediate Allogeneic Stem Cell Transplantation (alloSCT) for Relapsed or Refractory Acute Myeloid Leukemia (R/R AML) or High-Risk Myelodysplastic Syndromes (HR-MDS)
    Kevlicius, Lukas
    Smalinskaite, Tautvile
    Trociukas, Igoris
    Pileckyte, Regina
    Cekauskiene, Rita
    Davainis, Linas
    Daukelaite, Guoda
    Vaitekenaite, Vilmante
    Strumskyte, Juste
    Jaramine, Vaida
    Slobinas, Arturas
    Jucaitiene, Renata
    Slepikiene, Inga
    Bukauskas, Adomas
    Stoskus, Mindaugas
    Batiuskaite, Raminta
    Norvilas, Rimvydas
    Velceckiene, Vilma
    Valentine, Egle Gineikiene
    Dirse, Vaidas
    Griskevicius, Laimonas
    Zucenka, Andrius
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S328 - S329
12345